世界の非小細胞性肺癌治療薬市場...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 10
2.1 Disease Introduction 10
2.2 Epidemiology 11
2.3 Etiology and Pathophysiology 11
2.3.1 Adenocarcinoma 12
2.3.2 Squamous Cell Carcinoma 15
2.3.3 Large Cell Carcinoma 17
2.3.4 Immunotherapy 18
2.4 Symptoms 18
2.5 Diagnosis 18
2.6 Prognosis 21
2.7 Treatment 21
2.7.1 Treatment Algorithm 22
2.7.2 First-Line Treatment 26
2.7.3 Maintenance Therapy 33
2.7.4 Second-Line Therapy 35
2.7.5 Third-Line Therapy 39
2.7.6 Adjuvant Therapy 39
3 Marketed Products 41
3.1 Overview 41
3.2 Chemotherapies – Various 41
3.2.1 Cisplatin 41
3.2.2 Carboplatin 42
3.2.3 Vinorelbine 42
3.2.4 Paclitaxel 42
3.2.5 Docetaxel 43
3.2.6 Gemcitabine 43
3.3 Alimta – Eli Lilly 44
3.4 Abraxane – Celgene Corporation 45
3.5 Tarceva – Roche 46
3.6 Iressa – AstraZeneca 47
3.7 Gilotrif – Boehringer Ingelheim 48
3.8 Xalkori – Pfizer 49
3.9 Avastin (bevacizumab) – Roche 50
3.10 Marketed Products Heatmap 51
3.11 Conclusion 53
4 NSCLC Pipeline 54
4.1 Overview 54
4.2 Mechanisms of Action in the Pipeline 58
4.3 Clinical Trials 61
4.3.1 Failure Rate 61
4.3.2 Clinical Trial Duration 64
4.3.3 Clinical Trial Size 66
4.3.4 Clinical Trial Primary Endpoints 69
4.4 Late-Stage Pipeline Product Profiles 71
4.4.1 Custirsen – Teva Pharmaceutical Industries 71
4.4.2 Halaven – Eisai 72
4.4.3 Dacomitinib – Pfizer 74
4.4.4 Vargatef – Boehringer Ingelheim 75
4.4.5 Necitumumab – Eli Lilly 77
4.4.6 Ganetespib – Synta Pharmaceuticals 78
4.4.7 Zykadia– Novartis 79
4.4.8 Yervoy – Bristol Myers Squibb 80
4.4.9 Nivolumab – Ono Pharmaceuticals/Bristol-Myers Squibb 82
4.4.10 MK-3475 – Merck 83
4.4.11 RG7446 – Roche 84
4.4.12 Cyramza– Eli Lilly 84
4.4.13 Tavocept – BioNumerik Pharmaceuticals 86
4.4.14 Tecemotide – Merck Serono 87
4.4.15 Tertomotide – KAEL-GemVax 88
4.4.16 Lucanix – NovaRx Corporation 89
4.4.17 Bevacizumab Biosimilar – Various 91
4.5 Safety and Efficacy Heatmap 91
4.6 Conclusion 94
4.6.1 Product Competitiveness Framework 94
4.6.2 Future Treatment Algorithm 95
5 Market Forecast 98
5.1 Geographical Markets 98
5.1.1 Global Markets 99
5.1.2 North America 101
5.1.3 Top Five EU Countries 103
5.1.4 Japan 107
5.2 Drivers and Barriers 109
5.2.1 Drivers 109
5.2.2 Barriers 109
6 Strategic Consolidations 111
6.1 Major Co-Development deals 111
6.1.1 Merck Enters into Co-Development Agreement with Endocyte 112
6.1.2 Exelixis Enters into a Co-Development Agreement with Genentech 113
6.1.3 CancerVax Enters into an Agreement with CIMAB and YM Biosciences 113
6.1.4 SFJ Pharma Enters into Co-Development Agreement with Pfizer for Dacomitinib 113
6.1.5 OxOnc Development Enters into Co-Development Agreement with Pfizer for Crizotinib 113
6.2 Major Licensing Deals 114
6.2.1 Merck Serono Enters into Licensing Agreement with Ono Pharma 115
6.2.2 Astellas Pharma Enters into Licensing Agreement with Aveo Pharma 116
6.2.3 Clovis Oncology Enters into a Licensing Agreement with Avila Therapeutics 116
6.2.4 Novartis Enters into Licensing Agreement with Antisoma 116
6.2.5 Cell Therapeutics Enters into Licensing Agreement with Novartis 116
7 Appendix 118
7.1 References 132
7.2 Market Definition 137
7.3 Abbreviations 137
7.3.1 Research Methodology 138
7.3.2 Secondary Research 139
7.3.3 Marketed Product Profiles 139
7.3.4 Late-Stage Pipeline Candidates 140
7.3.5 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products 140
7.3.6 Product Competitiveness Framework 140
7.3.7 Pipeline Analysis 140
7.3.8 Forecasting Model 141
7.3.9 Deals Data Analysis 142
7.4 Contact Us 142
7.5 Disclaimer 143